Suvretta Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-50,300
Closed -$1.45M 110
2023
Q4
$1.45M Buy
+50,300
New +$1.52M 0.07% 72
2019
Q2
Sell
-1,348,909
Closed -$54.4M 56
2019
Q1
$54.4M Buy
1,348,909
+1,312,019
+3,557% +$52.5M 1.57% 25
2018
Q4
$1.53M Buy
+36,890
New +$1.53M 0.09% 18
2018
Q2
Sell
-52,700
Closed -$1.77M 28
2018
Q1
$1.77M Buy
+52,700
New +$1.81M 0.04% 21
2016
Q2
Sell
-6,729,685
Closed -$189M 33
2016
Q1
$189M Buy
6,729,685
+4,089,731
+155% +$117M 7.16% 5
2015
Q4
$80.9M Buy
2,639,954
+1,968,556
+293% +$61.9M 3.98% 14
2015
Q3
$20M Buy
+671,398
New +$21.5M 2.12% 11

Other funds holding PFE

Suvretta Capital Management's PFE Position: Q1 2024 in Review

Suvretta Capital Management sold out of Pfizer (PFE) in Q1 2024, closing a stake of 50,300 shares — an estimated $1.45M sold.

Suvretta Capital Management first reported a position in PFE in Q3 2015 and held it in 7 quarters. The position peaked at $189M in Q1 2016. 2,874 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

  • Suvretta Capital Management reported no remaining Pfizer position as of Q1 2024 after selling out during the quarter.
  • Suvretta Capital Management sold 50,300 Pfizer shares in Q1 2024, an estimated $1.45M.
  • Suvretta Capital Management first reported a position in Pfizer in Q3 2015 and held it in 7 quarters.
  • Suvretta Capital Management's Pfizer position peaked at $189M in Q1 2016.
  • 2,874 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on Suvretta Capital Management's 13F filing for Q1 2024, filed 15 May 2024.